Ascendis Pharma AS
(NAS:ASND)
$
137.5
-2.81 (-2%)
Market Cap: 8.39 Bil
Enterprise Value: 8.62 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 71/100 
Q2 2024 Ascendis Pharma A/S Earnings Call TranscriptSep 03, 2024$134.68 (-2.72%)Earnings- Q1 2024 Ascendis Pharma A/S Earnings Call TranscriptMay 02, 2024$141.1 (+0.06%)Earnings
- Q4 2023 Ascendis Pharma A/S Earnings Call TranscriptFeb 07, 2024$139.29 (-1.10%)Earnings
- Ascendis Pharma A/S at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Q3 2023 Ascendis Pharma A/S Earnings Call TranscriptNov 07, 2023$96.15 (+1.84%)Earnings
- Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Ascendis Pharma A/S at Citi BioPharma Conference TranscriptSep 07, 2023
- Q2 2023 Ascendis Pharma A/S Earnings Call TranscriptSep 05, 2023$99.74 (+1.50%)Earnings
- Ascendis Pharma A/S at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Ascendis Pharma A/S Oncology program update TranscriptMay 31, 2023
- Ascendis Pharma A/S at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Ascendis Pharma A/S Regulatory Update TranscriptMay 01, 2023
- Q1 2023 Ascendis Pharma A/S Earnings Call TranscriptApr 27, 2023$76.98 (+0.71%)Earnings
- Ascendis Pharma A/S Corporate Call TranscriptApr 03, 2023
- Q4 2022 Ascendis Pharma A/S Earnings Call TranscriptFeb 16, 2023$111.36 (-0.57%)Earnings
- Ascendis Pharma A/S at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Ascendis Pharma A/S Corporate Call TranscriptNov 14, 2022
- Q3 2022 Ascendis Pharma A/S Earnings Call TranscriptNov 02, 2022$113.94 (-2.37%)Earnings
- Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Ascendis Pharma A/S at Citi BioPharma Conference TranscriptSep 07, 2022
- Q2 2022 Ascendis Pharma A/S Earnings Call TranscriptAug 10, 2022$95.14 (+2.14%)Earnings
- Ascendis Pharma A/S at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q1 2022 Ascendis Pharma A/S Earnings Call TranscriptMay 11, 2022$78.08 (-5.52%)Earnings
- Ascendis Pharma A/S Announces Phase 3 PaTHway Trial Results Conference Call TranscriptMar 14, 2022
- Q4 2021 Ascendis Pharma A/S Earnings Call TranscriptMar 02, 2022$106.48 (-2.16%)Earnings
- Ascendis Pharma A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Ascendis Pharma A/S R&D Update TranscriptDec 14, 2021
- Q3 2021 Ascendis Pharma A/S Earnings Call TranscriptNov 10, 2021$153.06 (-3.58%)Earnings
- Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2021
- Q2 2021 Ascendis Pharma A/S Earnings Call TranscriptAug 25, 2021$123.67 (+1.57%)Earnings
- Q1 2021 Ascendis Pharma A/S Earnings Call TranscriptMay 27, 2021$136.19 (+1.81%)Earnings
- Ascendis Pharma A/S Presents At Bank of America Securities 2021 Healthcare Conference (Virtual) TranscriptMay 11, 2021
- Full Year 2020 Ascendis Pharma A/S Earnings Call TranscriptMar 10, 2021$143.99 (-0.74%)Earnings
- Ascendis Pharma A/S at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 24, 2021
- Ascendis Pharma A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Ascendis Pharma A/S - Special Call TranscriptNov 20, 2020
- Q3 2020 Ascendis Pharma A/S Earnings Call TranscriptNov 11, 2020$160 (-0.98%)Earnings
- Ascendis Pharma A/S - Special Call TranscriptSep 29, 2020
- Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Q2 2020 Ascendis Pharma A/S Earnings Call TranscriptAug 27, 2020$137.82 (-1.18%)Earnings
- Ascendis Pharma A/S at Canaccord Genuity Growth Conference (Virtual) TranscriptAug 12, 2020
- Ascendis Pharma A/S at Wedbush PacGrow Healthcare Virtual Conference TranscriptAug 11, 2020
- Q1 2020 Ascendis Pharma A/S Earnings Call TranscriptMay 19, 2020$143.19 (+1.72%)Earnings
- Ascendis Pharma A/S - Special Call TranscriptApr 19, 2020
- Q4 2019 Ascendis Pharma A/S Earnings Call TranscriptApr 01, 2020$113 (+0.35%)Earnings
- Ascendis Pharma A/S at Leerink Global Healthcare Conference TranscriptFeb 25, 2020
- Ascendis Pharma A/S at JPMorgan Healthcare Conference TranscriptJan 13, 2020
- Q3 2019 Ascendis Pharma A/S Earnings Call TranscriptNov 18, 2019$106.98 (-4.92%)Earnings
- Ascendis Pharma A/S at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Q2 2019 Ascendis Pharma A/S Earnings Call TranscriptAug 28, 2019$111.7 (-0.71%)Earnings
- Ascendis Pharma A/S - Special Call TranscriptJun 26, 2019
- Q1 2019 Ascendis Pharma A/S Earnings and Business Update Call TranscriptMay 30, 2019
- Ascendis Pharma A/S at Bank of America Merrill Lynch Health Care Conference TranscriptMay 14, 2019
- Full Year 2018 Ascendis Pharma A/S Earnings Call TranscriptApr 03, 2019$116.9 (+3.29%)Earnings
- Ascendis Pharma A/S - Special Call TranscriptMar 04, 2019
Ascendis Pharma A/S at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021 / 04:40PM GMT
Release Date Price:
$173.33
(+2.53%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst
Great. Good morning, everyone. My name is Jess Fye. I'm one of the Senior Biotech analysts at JPMorgan. And we're continuing the health care conference this morning with Ascendis. I'm joined by the company's CEO, Jan Mikkelsen, who's going to give a presentation. And to the extent there's time for Q&A at the end, you can submit questions to me on the portal by using the blue, ask a question, button.
But without further ado, let me turn it over to Jan.
Jan Moller Mikkelsen;S;President
Ascendis Pharma A;CEO, Member of Executive Board & Executive Director
/- -
So first, thank you a lot, Jess. And thank you to everyone for joining here today to hear about Ascendis.
And as a reminder, Slide 2, I will make forward-looking statement. Please refer to our SEC filing for associated risk factors.
So now I move to Slide 3. Yes, not as a big surprise. We are really sticking to our visions, our strategy. What we all are
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers